Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

The following table summarizes stock option activities for the nine months ended September 30, 2018:

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Options outstanding at December 31, 2017		1,241,675	$	5.73		9.31
Options granted		-		-		-
Options outstanding		1,241,675		5.73		8.56
Options vested and exercisable at September 30, 2018		194,011	$	5.73		8.56

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2018 and 2017 (in thousands).

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2017		2018		2017
Employee	$	734	$	576	$	2,457	$	909
Non-employee		169		258		1,412		321
Total stock-based compensation expense	$	903	$	834	$	3,869	$	1,230

A summary of warrant activities for nine months ended September 30, 2018 is presented below:

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2017		5,253,318		$	8.28		3.89
Granted		-			-		-
Exercised		(42,620	)		4.25		-
Outstanding as of September 30, 2018		5,210,698		$	8.32		3.35

The following table summarizes restricted stock award activities for the nine months ended September 30, 2018:

	Number of Shares		Weighted Average Grant Date Fair Value
Nonvested at December 31, 2017		180,000	$	5.73
Granted		50,000		7.89
Nonvested at September 30, 2018		230,000	$	6.20

The following table summarizes restricted stock units activities for the nine months ended September 30, 2018:

	Number of Units			Weighted Average Grant Date Fair Value
Nonvested at December 31, 2017		134,000		$	6.53
Granted		709,000			10.10
Vested		(127,500	)		9.31
Nonvested at September 30, 2018		715,500		$	9.58